Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Forum

Rhea-AI Summary

Avid Bioservices (NASDAQ:CDMO) announced participation in the KeyBanc Capital Markets Life Sciences & MedTech Forum on March 22-23, 2022. CEO Nick Green will feature in a fireside chat on March 23 from 1:30 - 2:05 p.m. Eastern. The event will be held virtually, and a live webcast will be available for attendees. Avid Bioservices specializes in biologics contract development and manufacturing, offering process development and CGMP manufacturing services for pharmaceutical companies. Visit avidbio.com for more details.

TUSTIN, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that the company will participate in the KeyBanc Capital Markets Life Sciences & MedTech Forum. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place March 22-23, 2022 in a virtual format.

Details of the company’s participation are as follows:

• KeyBanc Capital Markets Life Sciences & MedTech Forum 
  Conference Date: March 22-23, 2022
  Fireside Chat Time/Date: 1:30 - 2:05 p.m. Eastern on Wednesday, March 23, 2022
  Format: Virtual Conference; webcast available

To listen to the live webcast of the KeyBanc fireside chat, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO), an S&P SmallCap 600 company, is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 28 years of experience producing monoclonal antibodies and recombinant proteins, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

FAQ

What is the date and time of Avid Bioservices' fireside chat at the KeyBanc Forum?

Avid Bioservices' fireside chat is scheduled for March 23, 2022, from 1:30 - 2:05 p.m. Eastern.

Where can I watch the Avid Bioservices fireside chat?

You can watch the Avid Bioservices fireside chat live or access the archive on their investor events page at avidbio.com.

Who will represent Avid Bioservices at the KeyBanc Capital Markets Forum?

Nick Green, the president and CEO of Avid Bioservices, will represent the company at the forum.

What is the focus of Avid Bioservices?

Avid Bioservices focuses on contract development and manufacturing of biologics, including monoclonal antibodies and recombinant proteins.

What type of services does Avid Bioservices provide?

Avid Bioservices offers a range of services, including process development, CGMP clinical and commercial manufacturing, and regulatory submissions support.